For treatment, beta emitters (β) like Lutetium‐177 (177Lu) are central, and they have been shown to be effective in NETs and prostate cancer through therapies such as PRRT and PSMA‐targeted therapies.[78,168] Alpha emitters (α) such as actinium‐225 (225Ac) and radium‐223 (223Ra) are gaining importance in the treatment of advanced and resistance cases because of their high LET and low tissue penetration, making them suitable for the treatment of micrometastases.[95,178] For example, 225Ac‐PSMA‐617 is effective in treating 177Lu‐PSMA‐refractory mCRPC. The gene discussed is FOLH1; the disease is prostate carcinoma.